Loring Wolcott & Coolidge Fiduciary Advisors’s Abiomed Inc ABMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-15,692
Closed -$3.85M 614
2022
Q3
$3.85M Hold
15,692
0.05% 89
2022
Q2
$3.88M Sell
15,692
-8
-0.1% -$2.16K 0.05% 92
2022
Q1
$5.2M Sell
15,700
-790
-5% -$243K 0.05% 88
2021
Q4
$5.92M Hold
16,490
0.05% 87
2021
Q3
$5.37M Hold
16,490
0.05% 86
2021
Q2
$5.15M Hold
16,490
0.05% 87
2021
Q1
$5.26M Sell
16,490
-85
-0.5% -$27.2K 0.06% 82
2020
Q4
$5.37M Hold
16,575
0.06% 80
2020
Q3
$4.59M Sell
16,575
-385
-2% -$111K 0.06% 84
2020
Q2
$4.1M Buy
16,960
+490
+3% +$98.4K 0.06% 85
2020
Q1
$2.39M Buy
16,470
+545
+3% +$90.5K 0.04% 95
2019
Q4
$2.72M Buy
15,925
+1,620
+11% +$300K 0.04% 103
2019
Q3
$2.54M Buy
14,305
+4,695
+49% +$1.01M 0.04% 106
2019
Q2
$2.5M Buy
9,610
+9,602
+120,025% +$2.55M 0.04% 108
2019
Q1
$2K Hold
8
﹤0.01% 660
2018
Q4
$3K Hold
8
﹤0.01% 621
2018
Q3
$4K Hold
8
﹤0.01% 576
2018
Q2
$3K Hold
8
﹤0.01% 601
2018
Q1
$2K Hold
8
﹤0.01% 679
2017
Q4
$1K Hold
8
﹤0.01% 726
2017
Q3
$1K Buy
+8
New +$1.21K ﹤0.01% 759

Other funds holding ABMD

Loring Wolcott & Coolidge Fiduciary Advisors's ABMD Position: Q4 2022 in Review

Loring Wolcott & Coolidge Fiduciary Advisors sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 15,692 shares — an estimated $3.85M sold.

Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in ABMD in Q3 2017 and held it in 21 quarters. The position peaked at $5.92M in Q4 2021. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

  • Loring Wolcott & Coolidge Fiduciary Advisors reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
  • Loring Wolcott & Coolidge Fiduciary Advisors sold 15,692 Abiomed Inc shares in Q4 2022, an estimated $3.85M.
  • Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in Abiomed Inc in Q3 2017 and held it in 21 quarters.
  • Loring Wolcott & Coolidge Fiduciary Advisors's Abiomed Inc position peaked at $5.92M in Q4 2021.
  • 8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.